In support of the strategy of targeting the CDK4/6–cyclin D1 complex for more effective treatment of ependymomas, a study demonstrated that abemaciclib, compared to other CDK4/6 inhibitors, has a higher efficiency in passively crossing the BBB [20]. The gene discussed is CDK4; the disease is ependymoma.